Clinical Trial Update: Bristol-Myers Squibb Dasatinib Src Inhibition in Endometrial Cancer [EARLY_Phase 1]

View source ↗

Summary

The update notes the completion of an early-phase 1 trial evaluating dasatinib, a Src inhibitor, in endometrial cancer. The study was sponsored by the Universit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer

Drugs mentioned

• DASATINIB (Dasatinib)

Snippet

Sponsor: University of Virginia | Conditions: Endometrial Cancer | EARLY_Phase 1 | Status: COMPLETED